KRAS G13D

Clinical trials for KRAS G13D explained in plain language.

Never miss a new study

Get alerted when new KRAS G13D trials appear

Sign up with your email to follow new studies for KRAS G13D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

New pill targets Hard-to-Treat cancers: early trial recruits 554 patients

Disease control Recruiting now

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

Matched conditions: KRAS G13D

Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

KRAS G13D

Get alerted when new KRAS G13D trials appear

New pill targets Hard-to-Treat cancers: early trial recruits 554 patients